BioMarin Pharmaceutical Inc - Company Profile
Powered by 
All the data and insights you need on BioMarin Pharmaceutical Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date BioMarin Pharmaceutical Inc Strategy Report
- Understand BioMarin Pharmaceutical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioMarin Pharmaceutical Inc (BioMarin) is a biotechnology company that develops and commercializes innovative medicines for the treatment of rare genetic diseases and medical conditions such as Duchenne muscular dystrophy (DMD), achondroplasia, phenylketonuria (PKU), late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. The company focuses on developing breakthrough treatments for debilitating and life-threatening diseases. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facility in Novato, California. It conducts business operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.
Headquarters
United States of America
Address
105 Digital Dr, Novato, California, 94949-8703
Website
www.biomarin.com
Telephone
1 415 5066700
No of Employees
3,401
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BMRN (NASD)
Revenue (2022)
$2.4B
15.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
18.4%
(2022 vs 2021)
Market Cap*
$17.2B
Net Profit Margin (2022)
XYZ
2.7%
(2022 vs 2021)
* As of and is in US$
BioMarin Pharmaceutical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Naglazyme-Mucopolysaccharidosis Type VI (MPS VI) | VOXZOGO |
| Aldurazyme-MPS I | Palynnziq |
| Kuvan-Phenylketonuria (PKU) | Brineura |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In December, the company secured an investment from Elliott Investment Management. |
| 2023 | Contracts/Agreements | In November, the company announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A. |
| 2023 | Plans/Strategy | In June, the company announced its plans to present new data from the ROCTAVIAN gene therapy clinical trial program. |
Competitor Comparison
| Key Parameters | BioMarin Pharmaceutical Inc | Biogen Inc | Amicus Therapeutics Inc | Protalix BioTherapeutics Inc | Enzon Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Novato | Cambridge | Philadelphia | Hackensack | Cranford |
| State/Province | California | Massachusetts | Pennsylvania | New Jersey | New Jersey |
| No. of Employees | 3,401 | 7,570 | 517 | 208 | - |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard A. Meier | Chairman | Executive Board | 2023 | - |
| Alexander Hardy | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Brian R. Mueller | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 49 |
| Erin Burkhart | Vice President; Chief Accounting Officer | Senior Management | 2022 | - |
| C. Greg Guyer, Ph.D | Chief Technology Officer; Executive Vice President - Global Manufacturing and Technical Operations. | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward